Memantine Lactose Adduct (CAS 1159637-28-1)

Memantine lactose adduct, a novel compound, has attracted attention in neuroscientific research due to its potential as an agent for neurological disorders, particularly Alzheimer′s disease (AD). Mechanistically, memantine, a non-competitive antagonist of NMDA receptors, exhibits neuroprotective effects by modulating glutamatergic neurotransmission, thereby preventing excitotoxicity-induced neuronal damage. The conjugation of memantine with lactose facilitates its transport across the blood-brain barrier (BBB), enhancing its bioavailability in the central nervous system (CNS) and optimizing its efficacy. Research on memantine lactose adduct has primarily focused on elucidating its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), as well as its neuroprotective mechanisms in preclinical models of AD. Moreover, studies have explored its potential as a targer for AD, aiming to mitigate cognitive decline and delay disease progression by targeting NMDA receptor-mediated synaptic dysfunction and neuronal degeneration. Additionally, investigations into the safety profile and tolerability of memantine lactose adduct have been conducted to assess its suitability for long-term use in AD patients.